An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: Application to a pharmacokinetic study

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Razelle Kurzrock, Steven I. Sherman, Douglas W. Ball et al. · Journal of Clinical Oncology · 2011 · 551 citations · Full text

Medicine, Oncology, Pharmacology +17

Response to Cabozantinib in Patients with <i>RET</i> Fusion-Positive Lung Adenocarcinomas

Alexander Drilon, Lu Wang, Adnan Hasanovic et al. · Cancer Discovery · 2013 · 471 citations · Full text

Medicine, Oncology, Pharmacology +15

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

David C. Smith, Matthew R. Smith, Christopher J. Sweeney et al. · Journal of Clinical Oncology · 2012 · 443 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

Weon‐Kyoo You, Barbara Sennino, Casey W. Williamson et al. · Cancer Research · 2011 · 263 citations · Full text

Medicine, Oncology, Pharmacology +17